This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Shire Pharmaceuticals Group PLC
Drug Names(s): IGSC, Subcutaneous Human Immune Globulin, Cuvitru (EU)
Description: BioMedTracker has separate drug profiles for the intravenous and subcutaneous formulations of Gammagard, as well as the subcutaneous formulation using Halozyme's Enhanze technology. Please also see Gammagard and Gammagard (Subcutaneous) with Enhanze.
Gammagard (Subcutaneous) is a formulation of Gammagard 10% for subcutaneous delivery, with once weekly dosing. An investigational 20% concentration is being evaluated in the US and EU.
Gammagard is a preparation of a broad spectrum of immunoglobulins (antibodies) derived from large pools of human plasma, which can be used for antibody replacement.
Baxter and Baxalta
In March 2014, Baxter announced plans to create two separate, independent global healthcare companies one focused on developing and marketing biopharmaceuticals (Baxalta Incorporated) and the other on medical products. In July 2015, Baxalta Incorporated launched as a stand-alone biopharmaceutical company.
Shire and Baxalta
In January 2016, Shire and Baxalta announced that the boards of directors of both companies have reached an agreement under which Shire will combine with Baxalta. Under the agreement, Baxalta shareholders will receive $18.00 in cash and 0.1482 Shire ADS per Baxalta share. Based on Shire's closing ADS price on January 8, 2016, this implies a total current value of $45.57 per Baxalta share, representing an aggregate consideration of approximately $32 billion. The exchange ratio is based on Shire's 30-day trading day volume weighted average ADS price of $199.03 as of January 8, 2016, which implies a total value of...See full deal structure in Biomedtracker
Gammagard (Subcutaneous) News
Additional information available to subscribers only: